Tagged with S

Italy In a wide-ranging conversation, veteran general manager of Teva’s Italian Cluster Hubert Puech d’Alissac explores the reasons for the company’s growth in the region to become the generic market leader, post-COVID changes to the pharma industry, and the state of private-public relationships in Europe. Furthermore, d’Alissac touches on the responsibility…

Global Based on analysis from Crunchbase, read on for 2021’s largest VC investments into the biotech industry (which topped USD 65 billion last year) and 2021’s busiest biotech lead investors overall.   Made with Visme Infographic Maker   Made with Visme Infographic Maker

Korea Boasting a pharma market size of KRW 23.2 trillion (USD 19.2 billion) for 2020, South Korea is one of Asia’s leading pharma nations. Read on for a ranking of the country’s top five companies, whose revenues in the first half of 2021 topped KRW 3.5 trillion (USD 2.9 billion).  …

Global As the focus of the global COVID-19 pandemic response shifts downstream from the development and production of vaccines to vaccination campaigns themselves, IFPMA Director-General Thomas Cueni lays out the biopharmaceutical industry’s three new overarching priorities: supporting country readiness, contributing to equitable distribution, and driving innovation.   From the early days…

Spain Javier Urzay, deputy director of Farmaindustria, the leading pharma industry association in Spain, discusses the main dynamics shaping the sector, including record levels of R&D investment and clinical trials, their collaboration with European organizations to develop digital capabilities, and the need for better access, investment in manufacturing and increased collaboration…

Spain Biogen’s managing director for Spain, Sergio Teixeira, reflects on the company’s key role in transforming multiple sclerosis and spinal muscular atrophy as examples of the American biotech giant commitment to transforming neuroscience. The Portuguese executive also analyzes what he describes as a “positive” momentum for biosimilars in Spain amongst his…

Spain Bial’s general manager for Spain and global director of its epilepsy franchise, Ana Álvarez, highlights the importance of the country for the organization – representing 25 percent of overall sales –, explains how she is managing the lifecycle of Bial’s CNS and cardiovascular portfolio, the importance of sustainability, and  the…

USA In the wake of Access! 2022, the Association for Accessible Medicines (AAM)’s first in-person annual summit in two years, AAM President and CEO Dan Leonard gives his five takeaways from what he describes as a “rich, complex, and provocative” conference.   The generic and biosimilar supply chains continue to demonstrate…

Italy Sanofi’s Country Lead, President & Managing Director for Italy Marcello Cattani discusses his career track and explains the company’s broad manufacturing footprint in the country – where Sanofi has four plants. In addition, he comments on the imminent changes to the Italian healthcare system and how the organization is transforming…

Global Two years into his role, Ipsen’s EVP and Chief Medical Officer Prof. Dr. med. Steven Hildemann MD discusses his vision of patient-centricity and how he is leading a medical transformation that puts data-driven insights at the core and aims to make a real difference to both clinical practice and patients’…

UK Oxford Nanopore hogged the UK biotech headlines in 2021, raising GBP 195 million in a single venture capital round – the year’s largest – and scoring a GBP 350 million listing on the London Stock Exchange, according to new data from the UK BioIndustry Association (BIA) and Clarivate. See below…

Global Pfizer’s record-breaking year set the stage for a sound financial year for Big Pharma’s top ten, whose revenue grew on average 19.8 percent in 2021. Posting sales of over USD 80 billion, Pfizer pulled away from second placed Roche and is aiming to break the USD 100 billion barrier in…